This is a type of fungal infection in your lungs caused by a mold called Aspergillus. It often happens in people who are very sick or have had surgery, and it can be very serious.
Every report comes from a Lived member, sent anonymously.
Have you tried Vfend (Voriconazole) for Invasive Pulmonary Aspergillosis?
Invasive pulmonary aspergillosis is a serious lung infection caused by Aspergillus, a mold that grows on decaying leaves, compost and stored grain and is common indoors and outdoors. Most people breathe in its microscopic spores every day without harm, because a healthy immune system clears them. When the immune system is badly weakened, the mold can instead grow into lung tissue, causing a form of pneumonia that damages the lung and can spread through the bloodstream to other organs. Symptoms are often vague at first: fever, cough, chest pain, shortness of breath, chills or phlegm that may contain blood. In someone already being treated in the hospital, the main clue may simply be breathing that gets worse despite antibiotics. Because it usually affects people who are already seriously ill, it is a life-threatening infection that needs prompt diagnosis and treatment. Aspergillus causes other lung conditions that behave very differently. Allergic bronchopulmonary aspergillosis is an allergic reaction to the mold, mostly in people with asthma or cystic fibrosis. An aspergilloma is a fungus ball that grows inside an old lung cavity. Chronic forms develop slowly over months in previously damaged lungs. This page is about the invasive form.
The infection comes from inhaling Aspergillus spores, which are almost impossible to avoid. What decides whether illness develops is the state of a person's defenses. The classic risk is a long period with very low levels of neutrophils, the white blood cells that fight fungi, which can happen during intensive chemotherapy for leukemia and other blood cancers. Stem cell transplants (especially with graft-versus-host disease, where donor immune cells attack the body), organ transplants (particularly lung transplants), high doses of corticosteroids such as prednisone and other medicines that suppress the immune system also raise the risk. A second group has become more recognized: people who are critically ill in an intensive care unit (ICU). Severe influenza and severe COVID-19 can leave the lungs vulnerable, and advanced chronic obstructive pulmonary disease (COPD), severe liver disease such as decompensated cirrhosis and steroid treatment in the hospital add to the risk. Many of these patients have no long-standing immune problem. The infection does not reflect anything a person did wrong, and ordinary household mold exposure in a healthy person is not a meaningful cause.
Diagnosis is difficult because the symptoms look like many other lung infections and no single test settles the question. Doctors start with how likely the infection is, based on the person's immune status and illness, and then look for evidence of the mold in the lungs. A CT (computed tomography) scan of the chest is the key imaging test. It shows spots, nodules or cavities that a plain chest X-ray often misses. These patterns suggest the infection but do not prove it, since other infections can look similar. Bronchoscopy is often the next step. A thin, flexible tube passed through the mouth or nose into the airways is used to rinse a small area of lung with fluid (bronchoalveolar lavage). The fluid is examined under the microscope and grown in culture, and it is tested for galactomannan, a sugar released by growing Aspergillus, and for Aspergillus DNA by PCR (polymerase chain reaction). Galactomannan can also be measured in blood, and people at very high risk, such as some patients with leukemia, may have it checked regularly. A positive blood test prompts further testing, while a negative one does not rule the infection out. A tissue biopsy showing the mold invading the lung is the most definitive proof, but it is not always safe to obtain. In practice, doctors often classify the diagnosis as possible, probable or proven and may start treatment before every result is back.
Treatment centers on antifungal medicine, started as soon as the infection is strongly suspected. Voriconazole (Vfend) and isavuconazonium (Cresemba, which the body converts to isavuconazole) are the usual first choices. Both belong to the azole family of antifungals and can be given by vein in the hospital and later as pills. Liposomal amphotericin B, an older type of antifungal given by IV, is an alternative when azoles are unsuitable, though it can strain the kidneys. If the infection does not respond, doctors may switch drug families or add a second antifungal. Azole antifungals interact with many other medicines, including some transplant, cancer and heart drugs, so the full medication list needs review before and during treatment. Monitoring usually includes liver blood tests and heart rhythm checks (an ECG), and with voriconazole and posaconazole, measurements of the drug level in the blood to make sure the dose is effective without being toxic. Voriconazole can also cause temporary vision changes and sensitivity to sunlight. Treating the infection also means strengthening the body's defenses where possible. That can include lowering steroid or other immune-suppressing doses when it is safe to do so, and waiting for white blood cell counts to recover after chemotherapy. Surgery or a procedure to block a bleeding blood vessel is reserved for uncommon situations, such as a lesion near a major vessel or serious bleeding. Prevention matters for the highest-risk groups. People with prolonged low white cell counts during blood cancer treatment, and stem cell transplant recipients with severe graft-versus-host disease, are often given posaconazole (Noxafil), another azole, to keep the infection from starting.
Invasive pulmonary aspergillosis is treated over weeks to months, not days. For people with weakened immune systems, guidelines recommend at least 6 to 12 weeks of antifungal treatment, and often longer, depending on how the lungs respond and whether immunity recovers. People who developed it during a critical illness without a lasting immune problem may need a shorter course once they recover and leave intensive care. The outlook depends heavily on the underlying illness and on whether the immune system rebounds. Recovery is much more likely when white blood cell counts return or immune-suppressing medicines can be reduced. In intensive care patients, especially those on breathing machines, the infection carries a high risk of death on top of an already serious illness. Follow-up usually includes repeat chest CT scans, often around four to six weeks into treatment or sooner if things are not improving, and repeat galactomannan blood tests when the first result was positive. Many people switch from IV treatment to antifungal pills and finish the course at home, with regular blood tests to check liver function and drug levels.
If you have a weakened immune system, such as during chemotherapy, after a transplant or while taking high-dose steroids, contact your care team right away if you develop a fever. Also call them promptly about a new or worsening cough, chest pain, shortness of breath or phlegm streaked with blood. While taking an antifungal for this infection, let the care team know about any new medicine, yellowing of the skin or eyes, vision changes or a racing or irregular heartbeat, since these can reflect side effects or interactions. Call 911 for coughing up a large amount of blood or for severe difficulty breathing, because the infection can damage lung blood vessels and cause serious bleeding.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Invasive Pulmonary Aspergillosis is like, what's helped you, or ask the community a question.